比索洛尔对慢性阻塞性肺疾病合并心力衰竭患者心肺功能及炎症因子表达的影响研究

Effect of bisoprolol on cardiopulmonary function and expression of inflammatory factors in patients with chronic obstructive pulmonary disease complicated with heart failure

目的研究比索洛尔对慢性阻塞性肺疾病合并心力衰竭患者的心肺功能和炎症因子表达的影响。方法选择2015年7月～2017年8月来我院治疗的慢性阻塞性肺疾病合并心力衰竭患者34例,根据治疗方式不同可分成对照组和观察组两组。给予对照组患者常规慢梗阻合并心力衰竭的药物;观察组患者则是在此基础上再加以比索洛尔药物治疗。观察两组患者在治疗前后的心肺功能、炎症因子水平。结果两组患者在治疗后的心肺功能和炎症因子水平比较,差异有统计学意义(P <0.05)。观察组患者在治疗后的肺功能指标和心功能指标中的左心室射血分数都要明显高于对照组患者;观察组患者在治疗后的心功能指标(除左心室射血分数外)则要明显低于对照组患者;观察组患者在治疗后的炎症因子水平也要明显低于对照组患者。结论对慢性阻塞性肺疾病合并心力衰竭患者使用比索洛尔可以明显改善患者心肺功能,降低患者的炎症因子水平,增强了患者抵抗炎症的信心,在临床上应给予使用。

Objective To investigate the effects of bisoprolol on cardiopulmonary function and inflammatory factor expression in patients with chronic obstructive pulmonary disease and heart failure. Methods From July 2015 to August 2017,34 patients with chronic obstructive pulmonary disease complicated with heart failure were randomly selected as the subjects of this study,34 patients were divided into control group and observation group according to different treatment methods.Patients in the control group were given routine drugs for chronic obstruction complicated with heart failure,while patients in the observation group were treated with bisoprolol on this basis.Cardiopulmonary function and levels of inflammatory factors in two groups before and after treatment were observed. Results The results showed that there were significant differences in cardiopulmonary function and inflammatory factors between the two groups after treatment(P < 0.05).Specifically,the left ventricular ejection fraction of the patients in the observation group was significantly higher than that of the patients in the control group after treatment;In the observation group,the cardiac function index after treatment (except for left ventricular ejection fraction) was significantly lower than that of the control group;The level of inflammatory factors in the observation group was also significantly lower than that in the control group.There were no significant differences in these indexes between the two groups before treatment,and the difference was not statistically significant(P > 0.05). Conclusion From this we can know that the use of bisoprolol in patients with chronic obstructive pulmonary disease and heart failure can significantly improve the cardiopulmonary function of patients,reduce the level of inflammatory factors in patients,enhance the patient's confidence in resisting inflammation,and should be used clinically.